vs
豪洛捷（HOLX）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是美泰的1.2倍（$1.0B vs $862.2M），豪洛捷净利率更高（17.1% vs 7.1%，领先10.0%），美泰同比增速更快（4.3% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $-88.1M），过去两年豪洛捷的营收复合增速更高（1.5% vs -10.6%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
HOLX vs MAT — 直观对比
营收规模更大
HOLX
是对方的1.2倍
$862.2M
营收增速更快
MAT
高出1.8%
2.5%
净利率更高
HOLX
高出10.0%
7.1%
自由现金流更多
HOLX
多$303.3M
$-88.1M
两年增速更快
HOLX
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $862.2M |
| 净利润 | $179.1M | $61.0M |
| 毛利率 | 56.0% | 44.9% |
| 营业利润率 | 22.6% | — |
| 净利率 | 17.1% | 7.1% |
| 营收同比 | 2.5% | 4.3% |
| 净利润同比 | -10.9% | 251.4% |
| 每股收益（稀释后） | $0.79 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXMAT
| Q1 26 | — | $862.2M | ||
| Q4 25 | $1.0B | $1.8B | ||
| Q3 25 | $1.0B | $1.7B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $1.0B | $826.6M | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.1B |
净利润HOLXMAT
| Q1 26 | — | $61.0M | ||
| Q4 25 | $179.1M | $106.2M | ||
| Q3 25 | $187.2M | $278.4M | ||
| Q2 25 | $194.9M | $53.4M | ||
| Q1 25 | $-17.4M | $-40.3M | ||
| Q4 24 | $201.0M | $140.9M | ||
| Q3 24 | $178.6M | $372.4M | ||
| Q2 24 | $194.5M | $56.9M |
毛利率HOLXMAT
| Q1 26 | — | 44.9% | ||
| Q4 25 | 56.0% | 45.9% | ||
| Q3 25 | 55.6% | 50.0% | ||
| Q2 25 | 56.3% | 50.9% | ||
| Q1 25 | 37.5% | 49.4% | ||
| Q4 24 | 56.8% | 50.7% | ||
| Q3 24 | 56.4% | 53.1% | ||
| Q2 24 | 55.4% | 49.2% |
营业利润率HOLXMAT
| Q1 26 | — | — | ||
| Q4 25 | 22.6% | 8.0% | ||
| Q3 25 | 22.6% | 21.9% | ||
| Q2 25 | 24.9% | 7.7% | ||
| Q1 25 | -0.7% | -6.4% | ||
| Q4 24 | 22.5% | 9.6% | ||
| Q3 24 | 23.3% | 26.5% | ||
| Q2 24 | 24.1% | 7.7% |
净利率HOLXMAT
| Q1 26 | — | 7.1% | ||
| Q4 25 | 17.1% | 6.0% | ||
| Q3 25 | 17.8% | 16.0% | ||
| Q2 25 | 19.0% | 5.2% | ||
| Q1 25 | -1.7% | -4.9% | ||
| Q4 24 | 19.7% | 8.6% | ||
| Q3 24 | 18.1% | 20.2% | ||
| Q2 24 | 19.2% | 5.3% |
每股收益（稀释后）HOLXMAT
| Q1 26 | — | $0.20 | ||
| Q4 25 | $0.79 | $0.32 | ||
| Q3 25 | $0.84 | $0.88 | ||
| Q2 25 | $0.86 | $0.16 | ||
| Q1 25 | $-0.08 | $-0.12 | ||
| Q4 24 | $0.87 | $0.40 | ||
| Q3 24 | $0.75 | $1.09 | ||
| Q2 24 | $0.82 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $866.0M |
| 总债务越低越好 | $2.5B | $2.3B |
| 股东权益账面价值 | $5.2B | $2.1B |
| 总资产 | $9.2B | $6.3B |
| 负债/权益比越低杠杆越低 | 0.48× | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资HOLXMAT
| Q1 26 | — | $866.0M | ||
| Q4 25 | $2.4B | $1.2B | ||
| Q3 25 | $2.2B | $691.9M | ||
| Q2 25 | $1.9B | $870.5M | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $2.0B | $1.4B | ||
| Q3 24 | $2.3B | $723.5M | ||
| Q2 24 | $2.4B | $722.4M |
总债务HOLXMAT
| Q1 26 | — | $2.3B | ||
| Q4 25 | $2.5B | $2.3B | ||
| Q3 25 | $2.5B | $2.3B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.5B | $2.3B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.5B | $2.3B | ||
| Q2 24 | $2.5B | $2.3B |
股东权益HOLXMAT
| Q1 26 | — | $2.1B | ||
| Q4 25 | $5.2B | $2.2B | ||
| Q3 25 | $5.0B | $2.3B | ||
| Q2 25 | $4.8B | $2.2B | ||
| Q1 25 | $4.6B | $2.1B | ||
| Q4 24 | $4.8B | $2.3B | ||
| Q3 24 | $5.1B | $2.3B | ||
| Q2 24 | $5.0B | $2.0B |
总资产HOLXMAT
| Q1 26 | — | $6.3B | ||
| Q4 25 | $9.2B | $6.6B | ||
| Q3 25 | $9.0B | $6.6B | ||
| Q2 25 | $8.8B | $6.2B | ||
| Q1 25 | $8.5B | $6.2B | ||
| Q4 24 | $8.7B | $6.5B | ||
| Q3 24 | $9.2B | $6.5B | ||
| Q2 24 | $8.9B | $5.9B |
负债/权益比HOLXMAT
| Q1 26 | — | 1.11× | ||
| Q4 25 | 0.48× | 1.04× | ||
| Q3 25 | 0.50× | 1.03× | ||
| Q2 25 | 0.52× | 1.08× | ||
| Q1 25 | 0.55× | 1.10× | ||
| Q4 24 | 0.53× | 1.03× | ||
| Q3 24 | 0.49× | 1.01× | ||
| Q2 24 | 0.51× | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $-88.1M |
| 自由现金流率自由现金流/营收 | 20.5% | -10.2% |
| 资本支出强度资本支出/营收 | 1.4% | 7.6% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXMAT
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $796.6M | ||
| Q3 25 | $355.1M | $72.0M | ||
| Q2 25 | $343.3M | $-300.1M | ||
| Q1 25 | $169.4M | $24.8M | ||
| Q4 24 | $189.3M | $862.1M | ||
| Q3 24 | $367.0M | $155.8M | ||
| Q2 24 | $405.8M | $-252.9M |
自由现金流HOLXMAT
| Q1 26 | — | $-88.1M | ||
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — |
自由现金流率HOLXMAT
| Q1 26 | — | -10.2% | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — |
资本支出强度HOLXMAT
| Q1 26 | — | 7.6% | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — |
现金转化率HOLXMAT
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 7.50× | ||
| Q3 25 | 1.90× | 0.26× | ||
| Q2 25 | 1.76× | -5.62× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | 6.12× | ||
| Q3 24 | 2.05× | 0.42× | ||
| Q2 24 | 2.09× | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
MAT
暂无分部数据
